A Phase 1, Randomized, Double-Blind, Placebo-Controlled, First-In-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single and Multiple Ascending Oral Doses of SK-09 in Healthy Adult Participants
Latest Information Update: 18 Dec 2025
At a glance
- Drugs SK-09 (Primary)
- Indications Focal segmental glomerulosclerosis
- Focus Adverse reactions; First in man
- Sponsors Consun Pharmaceutical
Most Recent Events
- 18 Dec 2025 New trial record